|Articles|January 11, 2020

Recalls That Should Be on Your Radar—Week of January 5, 2020

We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

Lipari Foods Recalls Wedge Deli Sandwiches Due to Possible Listeria monocytogenes Contamination

Lipari Foods has issued a voluntary recall of various “Premo” and “Fresh Grab” wedge sandwiches due to potential contamination with Listeria monocytogenes. Listeria monocytogenes can cause serious infections in those with compromised immune systems such as children or older adults.

The problem was discovered by JLM manufacturing during environmental sampling which returned a positive test result for Listeria monocytogenes. There have been no illnesses reported in relation to the products to date.

Read the recall statement.

Appco Pharma Recalls Ranitidine Hydrochloride Capsules Due to Elevated N-Nitrosodimethylamine

Appco Pharma LLC has issued a voluntary recall of all quantities and lots of Ranitidine Hydrochloride Capsules due to the presence or potential presence of elevated N-nitrosodimethylamine levels above daily intake levels established by the FDA.

N-nitrosodimethylamine is classified as a likely human carcinogen. No adverse events have been reported related to the recall.

Read the recall statement.

Denton Pharma Recalls Ranitidine Tablets Due to Elevated N-Nitrosodimethylamine

Denton Pharma, Inc has issued a voluntary recall of all lots of Ranitidine Tablets, 150 mg and 300 mg, due to the presence or potential presence of elevated N-nitrosodimethylamine levels above daily intake levels established by the FDA.

No adverse events have been reported related to the recall.

Read the recall statement.

Mylan Recalls 3 Lots of Nizatidine Capsules Due to N-Nitrosodimethylamine Impurity

Mylan N.V. has issued a voluntary nationwide recall of 3 lots of Nizatidine Capsules due to trace amounts of N-nitrosodimethylamine.

Nizatidine is indicated for the short-term treatment of active duodenal ulcers and active benign gastric ulcers, as maintenance therapy for duodenal ulcer patients for up to 1 year, and for treatment of esophagitis and associated heartburn due to gastroesophageal reflux disease for up to 12 weeks.

Read the recall statement.

Fresh Location Recalls Snack Tray and Trail Mix Due to Possible Listeria monocytogenes Contamination

Fresh Location has issued a recall of Protein Snack Tray 6.44 oz and Protein Trail Mix 3.52 oz due to the potential to be contaminated with Listeria monocytogenes. The potential contamination is linked to Almark Foods, which manufactures hard-boiled eggs associated with a Listeria monocytogenes outbreak which has been linked to illnesses and 1 death.

There have not been any reports of adverse events related to the recalled Fresh Location products to date.

Read the recall statement.


Related to this article

Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.